Form D · Biotechnology
Taysha Gene Therapies, Inc.
Dallas, TX · CIK 0001806310
Offering snapshot reported Aug 25, 2023 · SEC filing
- Reported sold
- $150M Offering amount: $150M
- Investors reported
- 42 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 16, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 25, 2023 | Initial | $149,952,767 | No comparison | 42 | SEC filing |
| Nov 7, 2022 | Initial | $30,000,000 | No comparison | 1 | SEC filing |
| Aug 18, 2020 | Initial | $95,999,816 | No comparison | 26 | SEC filing |
| May 4, 2020 | Initial | $18,000,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $9M
- Form D file number
- 021-490724
The Company sold pre-funded warrants to purchase 44,250,978 shares of common stock. The purchase price was $0.90 minus the $0.001 exercise price per pre-funded warrant. If exercised, the Company will receive $0.001 for each pre-funded warrant.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Jefferies LLC | 2347 |
Source: Form D, filed Aug 25, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kamran Alam | Executive |
| Phillip Donenberg | Director |
| Paul B. Manning | Director |
| Sukumar Nagendran | Director, Executive |
| Sean P. Nolan | Director, Executive |
| Suyash Prasad | Executive |
| Kathleen Reape | Director |
| Laura Sepp Lorenzino | Director |
| R.A. Session Ii | Director, Executive |
| R. A. Session Ii | Director, Executive |
| Ra Session Ii | Director, Executive |
| Sean Stalfort | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3000 Pegasus Park Drive Suite 1430
Dallas, TX, 75247
Dallas, TX, 75247